Ajanta Pharma stated that it has signed an in-licensing deal with Biocon Ltd for semaglutide, a GLP-1 receptor agonist.

Ajanta Pharma announced in an exchange filing that Biocon will provide semaglutide for exclusive marketing in 23 countries and semi-exclusive marketing in three nations in Africa, the Middle East, and Central Asia.

Semaglutide is used to enhance glucose management in adults. In March 2026, the product patent will expire in the majority of these markets. Ajanta Pharma announced its intention to market the product following the acquisition of regulatory approvals anticipated in late 2026 or early 2027.

Yogesh Agrawal, Managing Director of Ajanta Pharma Ltd, stated, "GLP-1 therapies have gained swift international acceptance and have become blockbuster products around the globe. We are thrilled to collaborate with Biocon on semaglutide and bring this crucial therapy to markets where Ajanta has a solid local presence and extensive reach. We believe that we can develop semaglutide into a significant and rapidly growing brand in these nations in the coming years."

Also Read: Semicon India 2025: Designing A Self-Reliant Semiconductor Hub

Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Ltd, stated, "This collaboration with Ajanta Pharma is a strategic move to enhance the global reach of Biocon’s GLP-1 portfolio and optimize the value of our scientific investments in advanced peptide development."

Also Read: The Global Fintech Fest 2025: Enabling Finance for Better World

Ajanta Pharma shares closed down 1.14 percent during Tuesday's session. The stock has decreased by nearly 11 percent this year to date. Conversely, Biocon's shares closed 0.4 percent higher on Tuesday, marking an 8.7 percent increase for the year to date.

Also Read: 5 AI Initiatives by the Indian Government Driving National Growth

Ajanta Pharma runs 7 advanced manufacturing plants in India. From this, 6 sites produce finished formulations while 1 produces Active Pharmaceutical Ingredients (APIs), mainly for internal use. Strict regulators such as the US FDA and WHO have authorized our facilities located in Paithan, Maharashtra, and Dahej, Gujarat